124 results on '"I. Kedar"'
Search Results
2. A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer
- Author
-
I, Kedar, L, Walsh, G Reznick, Levi, S, Lieberman, A Abu, Shtaya, S Naftaly, Nathan, I, Lagovsky, R, Tomashov-Matar, M, Goldenberg, L, Basel-Salmon, L, Katz, O, Aleme, T Yablonski, Peretz, A, Hubert, D, Rothstein, S, Castellvi-Bel, T, Walsh, M C, King, C C, Pritchard, Z, Levi, E, Half, I, Laish, and Y, Goldberg
- Subjects
Adult ,Aged, 80 and over ,Adolescent ,Middle Aged ,Colorectal Neoplasms, Hereditary Nonpolyposis ,DNA Mismatch Repair ,Young Adult ,MutS Homolog 2 Protein ,Jews ,Humans ,Ethiopia ,Colorectal Neoplasms ,Germ-Line Mutation ,Aged - Abstract
Lynch syndrome is an inherited cancer predisposition syndrome caused by germline defects in any of the mismatch repair (MMR) genes. Diagnosis of carriers makes precision prevention, early detection, and tailored treatment possible. Herein we report a novel founder deletion of 18,758 bp, mediated by Alu repeats on both sides, detected in Ethiopian Jews. The deletion, which encompasses exon 9-10 of the MSH2 coding sequence, is associated mainly with early-onset MSH2/MSH6-deficient colorectal cancer (CRC) and liposarcoma. Testing of 35 members of 5 seemingly unrelated families of Ethiopian origin yielded 10/21 (48%) carriers, of whom 9 had CRC. Age at first tumor diagnosis ranged from 16 to 89 years. Carriers from the oldest generations were diagnosed after age 45 years (mean 57), and carriers from the younger generation were diagnosed before age 45 years (mean 30). Awareness of this founder deletion is important to improve patient diagnosis, institute surveillance from an early age, and refer patients for genetic counseling addressing the risk of bi-allelic constitutional MMR deficiency syndrome.
- Published
- 2020
3. Multi-parametric prostate MRI as a screening test among male BRCA carriers
- Author
-
D. Margel, S. Sela, S. Tamir, I. Kedar, Y. Ber, D. Kedar, A. Nadu, and J. Baniel
- Subjects
Urology - Published
- 2019
- Full Text
- View/download PDF
4. Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic
- Author
-
David Margel, Rachel Ozalvo, Yaara Ber, Ofer Benjaminov, Roy Mano, Sivan Sela, Jack Baniel, and I. Kedar
- Subjects
0301 basic medicine ,Gynecology ,Oncology ,medicine.medical_specialty ,business.industry ,Urology ,BRCA mutation ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,medicine ,business - Published
- 2017
- Full Text
- View/download PDF
5. Switching from Tacrolimus to Sirolimus Halts the Appearance of New Sebaceous Neoplasmsin Muir-Torre Syndrome
- Author
-
Eyal Gal, I. Kedar-Barnes, Eytan Mor, Zohar Levi, Rachel Hazazi, E. Hodak, Yaron Niv, and J. Winkler
- Subjects
Adenoma ,Male ,medicine.medical_specialty ,Pathology ,medicine.medical_treatment ,Liver transplantation ,Tacrolimus ,Muir–Torre syndrome ,Humans ,Immunology and Allergy ,Medicine ,Pharmacology (medical) ,Sebaceous Gland Neoplasms ,Antibacterial agent ,Immunosuppression Therapy ,Sirolimus ,Transplantation ,business.industry ,Immunosuppression ,Syndrome ,Middle Aged ,equipment and supplies ,medicine.disease ,Colorectal Neoplasms, Hereditary Nonpolyposis ,Kidney Transplantation ,Dermatology ,Calcineurin ,Regimen ,MutS Homolog 2 Protein ,surgical procedures, operative ,Mutation ,Disease Progression ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
Little is known about the effects of immunosuppression on patients with hereditary nonpolyposis colorectal cancer (HNPCC). We describe a kidney transplant recipient with unrecognized Muir-Torre syndrome in whom the administration of a tacrolimus-based regimen led to the eruption of multiple sebaceous tumors. The patient was later found to harbor an MSH2 mutation. Switching to a sirolimus-based regimen resulted in arrest of the disease. When the patient was switched back to tacrolimus, new facial lesions rapidly appeared. Switching again to sirolimus resulted again in halting the appearance of new lesions. This finding is in line with the known antiangiogenic activity of sirolimus and reports on the regression of cutaneous Kaposi's sarcoma in kidney transplant recipients switched from another immunosuppressive regimen to sirolimus. Further studies on the potential use of sirolimus for the treatment of de novo tumors in immunosuppressed kidney transplant recipients with HNPCC are warranted.
- Published
- 2007
- Full Text
- View/download PDF
6. [Untitled]
- Author
-
A. Amiel, Orit Reish, R. Diukman, I. Kedar, Moshe Fejgin, and E. Gaber
- Subjects
Genetics ,Proband ,Down syndrome ,Replication timing ,Meiosis ,Offspring ,medicine ,Aneuploidy ,Allele ,Biology ,medicine.disease ,Human genetics - Abstract
We attempted to demonstrate a relation between a loss of replication control, centromere dysfunction, and predisposition to non-disjunction. Couples with a Down syndrome offspring were the high-risk probands. One-color FISH (fluorescent in-situ hybridization) was applied to interphase nuclei (lymphocytes). Replication pattern of two pairs of alleles, RB-1 and 21q22, were studied, and the rate of aneuploidy was estimated using two alpha-satellite probes of chromosomes 8 and 18. Our results suggest the existence of an association between replication timing and the rate of non-disjunction. A higher rate of allele asynchrony and aneuploidy was found in older women and in mothers of a Down syndrome offspring. These findings may reflect a predisposition for meiotic non-disjunction in these women.
- Published
- 2000
- Full Text
- View/download PDF
7. Screening for Cytotoxic and Antimalarial Activities in Desert Plants of the Negev and Bedouin Market Plant Products
- Author
-
H. Lugasi-Evgi, P. Sathiyamoorthy, Jacob Gopas, I. Kedar, Avi Golan-Goldhirsh, P. Schlesinger, and Yaakov Pollack
- Subjects
Pharmacology ,Echinops ,Trigonella ,Gypsophila ,biology ,Pharmaceutical Science ,General Medicine ,biology.organism_classification ,Teucrium polium ,food.food ,Solanum elaeagnifolium ,food ,Phlomis ,Complementary and alternative medicine ,Peganum harmala ,Drug Discovery ,Botany ,Verbascum ,Molecular Medicine - Abstract
Aqueous extracts of 66 desert plants of the Negev and Beer Sheva Bedouin market plant products were tested for antitumor, antimalarial (protozoa) and growth inhibition of wheat-rootlet activities. Pteranthus dichotomus, Gypsophila arabica, Achillea fragrantissima, Urginea maritima, and Solanum elaeagnifolium exhibited strong cytotoxicity (above 97%) against cultured melanoma cell lines. Mesembryanthemum nodiflorum, Gypsophila arabica, Hammada scoparia, Trigonella foenum-graecum and Peganum harmala had more than 80% inhibition both in rootlet and melanoma assays. Hammada scoparia, Pulicaria crispa, Centaurea eryngioides, Echinops polyceras, Ephedra aphylla, Teucrium polium, Phlomis brachyodon, Urginea maritima, Ochradenus baccatus, Verbascum fruiticulosum, Corchorus olitorius, and Peganum harmala demonstrated strong growth inhibition (above 96%) of the malaria parasite Plasmodium falciparum. The plants that were positive for antimelanoma and antimalarial activities have been under further investigation for...
- Published
- 1999
- Full Text
- View/download PDF
8. Dilemma of trisomy 20 mosaicism detected prenatally: Is it an innocent finding?
- Author
-
I. Kedar, Moshe Fejgin, Orit Reish, Baruch Wolach, Aliza Amiel, and Tzipora Dolfin
- Subjects
Pathology ,medicine.medical_specialty ,Chromosomes, Human, Pair 20 ,Aneuploidy ,Trisomy ,Prenatal diagnosis ,Biology ,Diagnosis, Differential ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Clinical significance ,Genetics (clinical) ,Genetics ,Fetus ,medicine.diagnostic_test ,Mosaicism ,Infant ,medicine.disease ,Karyotyping ,Cord blood ,Amniocentesis ,Female ,Follow-Up Studies ,Fluorescence in situ hybridization - Abstract
The clinical significance of mosaicism trisomy 20 detected prenatally following amniocentesis remains uncertain, due to the rarity of liveborn cases with inconsistent clinical findings, the short postnatal follow-up, and failure in evaluating other fetal tissues for the presence of the trisomy. We report on a 15 month-old 46,XX chromosome constitution in white blood cells, while skin fibroblasts demonstrated trisomy 20 mosaicism (54%) by fluorescence in situ hybridization (FISH) analysis. Clinical examination of the baby showed only minor phenotypic signs (bilateral epicanthal folds, delayed closure of fontanel with no other gross anomalies), but demonstrated a considerable developmental delay in gross and fine motor skills along with hypotonicity. This is the second oldest described liveborn with trisomy 20 mosaicism confirmed in skin fibroblasts. This cytogenetic aberration along with her developmental delay suggests that the two findings are related and that aberration affects various fetal tissues and is not confined to extra-embryonic tissue as suggested previously. Yet, an undiagnosed condition may be the cause of the child's developmental delay. Based on this case and following a review of the literature we suggest that when mosaic trisomy 20 is identified in amniocytes, further evaluation is required. Cord blood should be analyzed preferably by FISH. During counseling the parents should be advised of an additional risk, such as developmental delay, even when fetal cord karyotype and detailed ultrasonic scan are normal.
- Published
- 1998
- Full Text
- View/download PDF
9. Elevated hCG as an isolated finding during the second trimester biochemical screen: genetic, ultrasonic, and perinatal significance
- Author
-
Yael Petel, I. Kedar, Ron Tepper, Moshe D. Fejgin, Talma Ben-Tovim, Rakefet Chen, and Aliza Amiel
- Subjects
Adult ,Down syndrome ,medicine.medical_specialty ,medicine.drug_class ,Chorionic Gonadotropin ,Ultrasonography, Prenatal ,Congenital Abnormalities ,Human chorionic gonadotropin ,Pregnancy ,Risk Factors ,medicine ,Humans ,Mass Screening ,Genetics (clinical) ,Chromosome Aberrations ,Fetus ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Pregnancy Outcome ,Case-control study ,Obstetrics and Gynecology ,medicine.disease ,Case-Control Studies ,Karyotyping ,Pregnancy Trimester, Second ,Amniocentesis ,Gestation ,Female ,Down Syndrome ,Gonadotropin ,business - Abstract
This study was undertaken in an attempt to determine the significance of elevated maternal serum human chorionic gonadotropin (MShCG), in the presence of an otherwise normal screen with respect to fetal malformations, chromosomal aberrations, and pregnancy outcome. Targeted ultrasound findings and perinatal outcome of 298 women in whom serum hCG was > or = 2.5 MOM and who were screen-negative for Down syndrome (the study group) were compared with a control group of 229 women in whom serum hCG as well as the other parameters were within the normal range. Genetic amniocentesis was performed in 125 women from the study group. Ultrasonically detected malformations were significantly more frequent among the study group (12 vs. 1, P = 0.01). Pregnancy complications were similar in the two groups, with the exception of pre-eclampsia-toxaemia, which was significantly more frequent in the study group (5 vs. 0, P = 0.02). There was one case of an abnormal karyotype (47,XXY). Although genetic amniocentesis does not appear warranted, isolated elevated MShCG levels during the second trimester screening was associated with an increased risk of fetal anomalies detected by ultrasound and of toxaemia of pregnancy.
- Published
- 1997
- Full Text
- View/download PDF
10. ARE ALL PHENOTYPICALLY-NORMAL TURNER SYNDROME FETUSES MOSAICS?
- Author
-
Aliza Amiel, Orit Reish, Moshe Fejgin, I. Kedar, Dvora Kidron, and E. Gaber
- Subjects
medicine.medical_specialty ,Fetus ,Pathology ,Gonad ,medicine.diagnostic_test ,Cytogenetics ,Obstetrics and Gynecology ,In situ hybridization ,Biology ,medicine.disease ,medicine.anatomical_structure ,Second trimester ,Turner syndrome ,medicine ,Amniocentesis ,%22">Fish ,Genetics (clinical) - Abstract
Cytogenetic and fluorescent in situ hybridization (FISH) studies were performed on several formalin-fixed tissues obtained from four fetuses diagnosed at amniocentesis as 45,XO-Turner syndrome. Three of the four were phenotypically normal and one had malformations. The three phenotypically normal cases were found to have an additional normal cell line, which may explain their ability to survive, at least to the time of pregnancy termination well into the second trimester. The abnormal 45,XO fetus was not found to be mosaic in all of the tissues examined. In 45,XO cases in which no malformation is detected, the possibility of mosaicism should be raised and thus the counselling should be modified accordingly.
- Published
- 1996
- Full Text
- View/download PDF
11. Differential Diagnosis and Management of Very Low Second Trimester Maternal Serum Unconjugated Estriol Levels, With Special Emphasis on the Diagnosis of X-Linked Ichthyosis
- Author
-
I Kedar, Yaron Zalel, Arie Drugan, Yoram Beyth, R Chen, Moshe Fejgin, and Ronnie Tepper
- Subjects
Adult ,medicine.medical_specialty ,X Chromosome ,Amniotic fluid ,Genetic Linkage ,Genetic counseling ,Prenatal diagnosis ,Diagnosis, Differential ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Gynecology ,Fetus ,X-linked ichthyosis ,Estriol ,Ichthyosis ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Pregnancy Trimester, Second ,Female ,Differential diagnosis ,business ,Biomarkers - Abstract
Incorporation of maternal serum unconjugated estriol into the calculation of risk may increase the yield of serum screening performed during pregnancy for detection of fetal chromosomal and structural anomalies. The differential diagnosis of very low and undetectable levels of unconjugated estriol in maternal serum is discussed, with special emphasis on the prenatal diagnosis of X-linked ichthyosis. The prenatal detection of these findings dictates skilled genetic counseling, targeted sonographic evaluation and examination of fetal karyotype and fetal cDNA for Xp 22.32 with amniotic fluid levels of cortisol, STS, and ASC.
- Published
- 1996
- Full Text
- View/download PDF
12. Fluorescent in-situ hybridization (FISH) as an aid to marker chromosome identification in prenatal diagnosis
- Author
-
I. Kedar, A. Bachar, Moshe Fejgin, Z. Appelman, Aliza Amiel, Elena Gaber, R. Zamir, M. Golbus, and I. Shapiro
- Subjects
Adult ,Genetic Markers ,Male ,medicine.medical_specialty ,X Chromosome ,Marker chromosome ,Prenatal diagnosis ,Biology ,Y chromosome ,Polymerase Chain Reaction ,Pregnancy ,Prenatal Diagnosis ,Y Chromosome ,medicine ,Humans ,Small supernumerary marker chromosome ,In Situ Hybridization, Fluorescence ,X chromosome ,Chromosome Aberrations ,medicine.diagnostic_test ,Cytogenetics ,Obstetrics and Gynecology ,Karyotype ,Molecular biology ,Reproductive Medicine ,Karyotyping ,Amniocentesis ,Female ,Chromosomes, Human, Pair 18 ,Fluorescence in situ hybridization - Abstract
Five cases of supernumerary marker chromosomes were identified in prenatal diagnosis as derived from chromosomes 18, X, and Y. One unexpected finding was in a case where the PCR was positive for the SRY gene while fluorescence in situ hybridization was positive for two X centromeres. In another case with an X derived supernumerary marker the newborn was phenotypically normal. Two women with fetal mar(18) and mar(Xp) decided to terminate the pregnancy. The fifth pregnancy had a karyotype of 46,XX,-15,+der(15)t(Y:15)(q11,23;p13). A phenotypically normal girl was born at term.
- Published
- 1995
- Full Text
- View/download PDF
13. Allogeneic Human Liposomal Melanoma Vaccine with or without IL-2 in Metastatic Melanoma Patients: Clinical and Immunobiological Effects
- Author
-
L. K. Bar, Jacob Schachter, Tirza Klein, Y. Barenholz, Aaron Sulkes, R. Michowiz, R. Korytnaya, Y. Cohen, A. Adler, and I. Kedar
- Subjects
Adult ,Cytotoxicity, Immunologic ,Male ,Cancer Research ,Lymphocyte ,medicine.medical_treatment ,Pilot Projects ,T-Lymphocytes, Regulatory ,Monocytes ,Melanoma Vaccine ,Immune system ,Antigen ,Antigens, Neoplasm ,In vivo ,Tumor Cells, Cultured ,medicine ,Humans ,Hypersensitivity, Delayed ,Melanoma ,Aged ,Pharmacology ,Vaccines ,business.industry ,Immunotherapy ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Neoplasm Proteins ,Treatment Outcome ,medicine.anatomical_structure ,Delayed-Action Preparations ,Antigens, Surface ,Liposomes ,Immunology ,Interleukin-2 ,Female ,Lymphocyte Culture Test, Mixed ,Melanoma-Specific Antigens ,Cimetidine ,business - Abstract
The aim of this pilot study was to assess the clinical and immunological effects of human allogeneic liposomal melanoma vaccine alone or combined with Interleukin-2 (IL-2) in patients with metastatic melanoma. Four concurrent treatment arms were included: vaccine alone (A); vaccine combined with systemic IL-2 (B); vaccine combined with low-dose liposomal regional IL-2 (C); and low-dose regional IL-2 as in group C but without vaccine (D). Vaccine was prepared from semisynthetic phospholipids (dimyristol phosphatidylcholine and dimyristol phosphatidylglycerol) and membranes of six human melanoma cell lines. The latter were chosen as expressing MHC class I and II antigens and a "mosaic" of melanoma-associated antigens (MAAs) as detected by MoAbs R24, p97, CF21 and TA99. Nine of the 24 patients had objective clinical responses: of the ten patients treated with liposomal vaccine and low dose regional IL-2 (arm C), three had complete responses (CR) and three had partial responses (PR); of the five patients treated with liposomal, low-dose regional liposomal IL-2 only (arm D), three had PRs. No clinical responses were seen in patients treated by vaccine alone (A) nor in patients treated by vaccine and systemic IL-2 (B). Patients' in vivo and in vitro cellular immune responses were closely monitored. Conversion to positive cutaneous delayed type hypersensitivity (DTH) to membrane vaccine (without liposomes) was induced only in the six clinical responders of arm C. Positive DTH correlated with augmented in vitro proliferative lymphocyte responses stimulated by melanoma cell lines and membrane preparation and with the augmented cytolytic activity against melanoma cell lines.
- Published
- 1995
- Full Text
- View/download PDF
14. A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%
- Author
-
I. Kedar, M. Tohar, Moshe Fejgin, Talma Ben-Tovim, Hagai Kaneti, Y. Petel, Aliza Amiel, and Doron J.D. Rosen
- Subjects
Adult ,medicine.medical_specialty ,Down syndrome ,Pregnancy, High-Risk ,Population ,Prenatal diagnosis ,Gestational Age ,Chorionic Gonadotropin ,Sensitivity and Specificity ,Ultrasonography, Prenatal ,Pregnancy ,Prenatal Diagnosis ,medicine ,Humans ,Advanced maternal age ,education ,Genetics (clinical) ,Chromosome Aberrations ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Estriol ,Triple test ,Obstetrics and Gynecology ,Gestational age ,Middle Aged ,medicine.disease ,Surgery ,Karyotyping ,Amniocentesis ,Female ,alpha-Fetoproteins ,Down Syndrome ,business ,Trisomy ,Maternal Age - Abstract
Objective A study was conducted to evaluate the sensitivity of combining a second trimester triple test and targeted ultrasound in order to detect Down syndrome in women undergoing amniocentesis over 35 years of age. Methods Women over 35 years of age underwent a triple test and an ultrasound examination for chromosomal markers immediately prior to genetic amniocentesis. Results One thousand and six women were examined. Four hundred and thirty seven were triple test-positive and in 195 cases ultrasonographic abnormalities were observed. Thirteen had Down syndrome and eight had other chromosomal abnormalities. All women with Down syndrome babies were triple test-positive and seven also had ultrasonographic markers. Three of eight women who had babies with chromosomal aberrations other then Down syndrome were also triple test-positive. Conclusions The use of the triple test as a screening tool in our population would reduce the number of amniocenteses by 60%, while no cases of Down syndrome would be missed. Ultrasonographic markers have added little to this population. Three non-Down syndrome chromosomal abnormalities and two Down syndrome mosaic cases would be missed by this approach. Copyright © 2002 John Wiley & Sons, Ltd.
- Published
- 2002
15. Replication asynchrony increases in women at risk for aneuploid offspring
- Author
-
A, Amiel, O, Reish, E, Gaber, I, Kedar, R, Diukman, and M, Fejgin
- Subjects
Adult ,DNA Replication ,Male ,Chromosomes, Human, Pair 21 ,Centromere ,Mothers ,Middle Aged ,Aneuploidy ,Fathers ,Nondisjunction, Genetic ,Risk Factors ,Humans ,Female ,Lymphocytes ,Down Syndrome ,Chromosomes, Human, Pair 18 ,Alleles ,In Situ Hybridization, Fluorescence ,Chromosomes, Human, Pair 8 ,Microsatellite Repeats - Abstract
We attempted to demonstrate a relation between a loss of replication control, centromere dysfunction, and predisposition to non-disjunction. Couples with a Down syndrome offspring were the high-risk probands. One-color FISH (fluorescent in-situ hybridization) was applied to interphase nuclei (lymphocytes). Replication pattern of two pairs of alleles, RB-1 and 21q22, were studied, and the rate of aneuploidy was estimated using two alpha-satellite probes of chromosomes 8 and 18. Our results suggest the existence of an association between replication timing and the rate of non-disjunction. A higher rate of allele asynchrony and aneuploidy was found in older women and in mothers of a Down syndrome offspring. These findings may reflect a predisposition for meiotic non-disjunction in these women.
- Published
- 2000
16. Genetic diagnosis from formalin-fixed fetal tissue using FISH: a new tool for genetic counseling in subsequent pregnancies
- Author
-
Ronnie Tepper, Yoram Beyth, Elena Gaber, Aliza Amiel, Deborah Kidron, Moshe D. Fejgin, and I. Kedar
- Subjects
Pathology ,medicine.medical_specialty ,Tissue Fixation ,Genetic counseling ,Fetal tissue ,Aneuploidy ,Chromosome Disorders ,Pregnancy ,Formaldehyde ,medicine ,Humans ,In Situ Hybridization, Fluorescence ,Genetic testing ,Retrospective Studies ,Chromosome Aberrations ,Fetus ,Paraffin Embedding ,medicine.diagnostic_test ,business.industry ,Obstetrics and Gynecology ,Karyotype ,Formalin fixed ,medicine.disease ,Fetal Diseases ,Reproductive Medicine ,%22">Fish ,Feasibility Studies ,Female ,business - Abstract
We evaluated the feasibility of retrospective genetic testing for numerical chromosomal aberrations by applying the FISH technique to formalin-fixed fetal tissue. Fetal tissue from 10 old cases with known aneuploidy and from 13 cases with known fetal malformations, were tested with specific DNA probes for pericentromeric repeat regions of chromosomes 13/21, 18, X and Y. FISH diagnosis concurred with karyotype in all nine cases with sufficient cells. Numerical aberration was diagnosed in six out of 13 cases with fetal malformations.
- Published
- 1996
17. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine
- Author
-
W J, Urba, L C, Hartmann, D L, Longo, R G, Steis, J W, Smith, I, Kedar, S, Creekmore, M, Sznol, K, Conlon, and W C, Kopp
- Subjects
Cytotoxicity, Immunologic ,HLA-D Antigens ,Phosphatidylethanolamines ,Lipopolysaccharide Receptors ,Antigens, Differentiation, Myelomonocytic ,Antineoplastic Agents ,Receptors, Fc ,Biopterin ,Neopterin ,Blood Cell Count ,Interferon-gamma ,C-Reactive Protein ,Antigens, CD ,Liposomes ,Drug Evaluation ,Humans ,Acetylmuramyl-Alanyl-Isoglutamine - Abstract
Muramyl tripeptide phosphatidylethanolamine (MTP-PE; CGP 19835A from Ciba Geigy) is a synthetic muramyl tripeptide structurally related to bacterial cell wall constituents. MTP-PE activates monocytes in vitro to a tumoricidal state and has in vivo antitumor effects in animal models. We studied the toxicity and immunomodulatory effects of once weekly i.v. administration of liposomal-encapsulated MTP-PE for 8 weeks in 27 patients with advanced malignancies. Doses ranged from 0.1 to 2.7 mg/m2. No major tumor responses were seen; 11 patients had stable disease after 8 weeks of therapy and 3 continued on maintenance therapy because of minor tumor regressions and/or clinical improvement. MTP-PE at these doses was well tolerated. Shaking chills and fevers were the most common toxicities and occurred at all dose levels. There was no treatment-induced loss of performance status. Immunomodulatory studies revealed evidence of a biological effect on monocytes. C-reactive protein levels rose in the majority of patients with end-of-treatment values 2 to 10 times higher than baseline. Serum neopterin levels were consistently increased 24 h after MTP-PE administration and significant decreases in expression of two different types of Fc receptors on peripheral blood monocytes were noted 6 h after treatment. Although no major tumor responses were seen in this group of patients with advanced malignancies, MTP-PE was well tolerated and exerted biological effects on monocytes. Serum neopterin levels may be a useful marker for the biological effects of MTP-PE.
- Published
- 1990
18. A noninvasive screening of systemic reactive (secondary) AA amyloidosis, based on reduced amyloid degrading activity of amyloidotic serum
- Author
-
M, Ravid, Y, Greenman, J, Shapira, and I, Kedar
- Subjects
Adult ,Male ,Amyloid ,Adipose Tissue ,Humans ,Mass Screening ,Female ,Amyloidosis ,Middle Aged ,Serum Albumin ,Aged - Abstract
Standardization of the measurement of amyloid degrading activity (ADA) by diffusion of serum in amyloid-impregnated agar plates may either indicate or exclude with reasonable certainty the presence of systemic AA amyloidosis. In certain cases, it may obviate the need for a diagnostic biopsy. The sera of 38 patients with systemic amyloidosis were tested and compared with sera of 38 controls matched for age, serum creatinine and albumin blood levels, and with sera of 48 additional controls with the same basic diseases as the amyloidotic patients but without amyloidosis. The difference between ADA of amyloidotic and control patients was significant, with no overlap in the range of activity between the two groups. A positive correlation was found between ADA and serum albumin concentration in the nonamyloidotic matched controls but not in patients with amyloidosis. Our data do not support the view that the decline in ADA of sera of amyloidotic patients is due to hypoalbuminemia.
- Published
- 1990
19. Recurrent anencephaly as a primary manifestation of the acrocallosal syndrome
- Author
-
Arie Drugan, Aliza Amiel, I. Kedar, and Moshe Fejgin
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Anencephaly ,Medicine ,business ,Acrocallosal syndrome ,medicine.disease ,Genetics (clinical) - Published
- 1996
- Full Text
- View/download PDF
20. Debris containing cystic transformation of melanoma metastatic lesions following chemoimmuno-therapy
- Author
-
Wilmosh Mermershtain, Y.S Cohen, and I Kedar
- Subjects
Cancer Research ,Transformation (genetics) ,Pathology ,medicine.medical_specialty ,Metastatic lesions ,Oncology ,business.industry ,Melanoma ,Medicine ,Dermatology ,business ,medicine.disease - Published
- 1997
- Full Text
- View/download PDF
21. Chemoimmunotherapy treatment of progressive disseminated melanoma patients, induced extension in survival
- Author
-
M Zarfati, Wilmosh Mermershtain, Y.S Cohen, and I Kedar
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Chemoimmunotherapy ,Internal medicine ,Melanoma ,medicine ,Dermatology ,business ,medicine.disease - Published
- 1997
- Full Text
- View/download PDF
22. CLINICAL AND IMMUNOLOGICAL EFFECTS OF ALLOGENEIC HUMAN LIPOSOMAL MELANOMA VACCINE WITH/WITHOUT IL-2 AN UPDATE
- Author
-
T. Prigozhina, V Barenholz, T. Klein, A. Adler, I. Kedar, and J Schachter
- Subjects
Pharmacology ,Cancer Research ,business.industry ,Immunology ,Immunology and Allergy ,Medicine ,business ,Melanoma Vaccine - Published
- 1993
- Full Text
- View/download PDF
23. Effect of liposomal allogeneic melanoma vaccine with IL-2 on cellular immune responses
- Author
-
Y. Cohen, I. Kedar, A. Adler, T. Klein, A. Sulkes, T. Prigozhina, Jacob Schachter, and Y. Barenholz
- Subjects
Cancer Research ,Liposome ,Immune system ,Oncology ,business.industry ,Immunology ,Medicine ,business ,Melanoma Vaccine - Published
- 1993
- Full Text
- View/download PDF
24. CELLULAR IMMUNE RESPONSE OF MELANOMA PATIENTS TREATED BY LIPOSOMAL ALLOGENEIC VACCINE WITH EITHER SYSTEMIC OR REGIONAL IL-2
- Author
-
A. Sulkes, A. Adler, Jacob Schachter, I. Kedar, and Y. Cohen
- Subjects
Pharmacology ,Cancer Research ,Liposome ,Immune system ,business.industry ,Melanoma ,Immunology ,medicine ,Immunology and Allergy ,medicine.disease ,business - Published
- 1993
- Full Text
- View/download PDF
25. THE PROTECTIVE EFFECT OF DIMETHYL SULFOXIDE IN EXPERIMENTAL ISCHEMIA OF THE INTESTINE
- Author
-
D. Van‐Dyk, Joëlle Bernheim, M. Ravid, and I. Kedar
- Subjects
Male ,Necrosis ,Perforation (oil well) ,Ischemia ,Peritonitis ,General Biochemistry, Genetics and Molecular Biology ,History and Philosophy of Science ,Intestinal mucosa ,medicine.artery ,Intestine, Small ,medicine ,Animals ,Dimethyl Sulfoxide ,Superior mesenteric artery ,Intestinal Mucosa ,Gangrene ,business.industry ,General Neuroscience ,medicine.disease ,Small intestine ,Rats ,medicine.anatomical_structure ,Anesthesia ,medicine.symptom ,business - Abstract
Experiments with two models of intestinal ischemia were performed in order to examine the protective effect of dimethyl sulfoxide (DMSO). Segmental ischemia of the small intestine for 150 minutes caused necrosis of the affected bowel in 90% of the animals. Intravenous administration of DMSO or impregnation of the peritoneum with this substance prevented the development of gangrene in 28 of 29 rats. 30 or 60 minutes of complete ischemia of the small intestine, produced by clamping of the superior mesenteric artery, resulted in partial or complete necrosis of bowel segments with a high incidence of perforation and peritonitis and a high mortality rate within the first 24 hours. Intravenous DMSO, given upon declamping of the artery, effectively protected the bowel from the ischemic damage. There were no deaths among DMSO-treated animals and at 24 h there was no evidence of ischemic damage to the intestine. Though the exact mechanism of action of DMSO is unknown, the results of these and other experiments may warrant clinical trials especially in cases of mesenteric thrombosis.
- Published
- 1983
- Full Text
- View/download PDF
26. Growth regulation of transformed T cells by nonactivated macrophages: the role of Ia expression
- Author
-
I Kedar, Y J Rosenberg, and A D Steinberg
- Subjects
Immunology ,Immunology and Allergy - Abstract
We studied the influence of unactivated mouse peritoneal macrophages on the proliferative capacity of a spontaneously transformed MRL-lpr/lpr T cell clone. Macrophages, 25%, induced a reduction in proliferative rate from 20% to 95% measured by [3H]thymidine incorporation and microscopic cytometry. MHC-compatible (H-2k) macrophages caused growth inhibition reciprocal to the amount of Ia expression on the macrophage. Thus, with increasing preculture of the macrophages there was both decreasing Ia and increasing suppression. H-2-incompatible macrophages had maximal inhibitory capacity without preincubation. Macrophages derived from the peritoneum of MRL-lpr/lpr mice were less suppressive than macrophages from other H-2k mice. In contrast to the case of activated macrophages in other studies, in the present system there was no killing of T cells, only reduction in proliferation. The inhibitory effect of the macrophages correlated with the spontaneous formation of rosettes between the macrophages and the T cell clone. The number of rosettes forming a single layer of T cells around the macrophages, but not the number of rosettes with multiple layers of cells, was reciprocally related to the amount of Ia expression. The results suggest that macrophages bear a surface structure that influences and modulates the growth of T cells.
- Published
- 1986
- Full Text
- View/download PDF
27. The role of polymorphonuclear leucocytes and T lymphocytes in experimental murine amyloidosis
- Author
-
M. Ravid and I. Kedar
- Subjects
Pathology ,medicine.medical_specialty ,Neutrophils ,T-Lymphocytes ,Clinical Biochemistry ,Mice, Nude ,Biochemistry ,Polymorphonuclear leucocyte ,Mice ,Colchicine treatment ,Casein ,Animals ,Transplantation, Homologous ,Medicine ,Transfer model ,Lymph node ,Ascitic fluid ,business.industry ,Amyloidosis ,Caseins ,General Medicine ,T lymphocyte ,medicine.disease ,Molecular biology ,medicine.anatomical_structure ,Colchicine ,business ,Spleen - Abstract
Washed cells, from ascitic fluid, which contained predominantly polymorphonuclear leucocytes from casein treated donor mice, induced accelerated amyloid formation in untreated syngeneic recipient animals. A similar transfer model, with lymph node cell suspension, was ineffective. Amyloidogenesis was completely blocked by colchicine treatment of the donors while treatment of the recipients had no effect. A casein induced amyloidogenic stimulus was transferred from nude C3H mice to their normal litter-mates. When the order was reversed, no amyloidosis occurred in the nude recipients. These experiments indicate the possible involvement of two cells in the biphasic process of casein induced murine amyloid formation: the polymorphonuclear leucocyte in the first phase and the T lymphocyte in the second.
- Published
- 1980
- Full Text
- View/download PDF
28. Treatment of experimental murine amyloidosis with dimethyl sulfoxide
- Author
-
M. Greenwald, M. Ravid, and I. Kedar Keizman
- Subjects
medicine.medical_specialty ,Amyloid ,medicine.medical_treatment ,Clinical Biochemistry ,Spleen ,Urine ,Biochemistry ,chemistry.chemical_compound ,Mice ,Internal medicine ,medicine ,Animals ,Dimethyl Sulfoxide ,Amyloid fibres ,Saline ,Dimethyl sulfoxide ,Amyloidosis ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,Amyloid deposition ,Endocrinology ,chemistry - Abstract
Dimethyl sulfoxide was administered intravenously for 60 days to twenty mice with casein-induced amyloidosis. Partial or total disappearance of amyloid deposits occurred in all treated animals. The urine of these animals contained a substance from which amyloid fibrils could be synthesized. A control group of mice with casein-induced amyloidosis given saline injections showed massive amyloid deposition in the liver and in the spleen at the end of the experiment. Neither the urine of these mice nor the urine of normal control mice treated with dimethyl sulfoxide contained substances from which amyloid fibrils could be synthesized. It is our assumption that dimethyl sulfoxide treatment of mice with amyloidosis resulted in a break up of amyloid fibres into small subunits which were excreted in the urine.
- Published
- 1977
29. Insulin-dependent casein-induced amyloidosis in experimental animals
- Author
-
I, Kedar, M, Greenwald, and M, Ravid
- Subjects
Amyloid ,Mice ,Animals ,Caseins ,Insulin ,Amyloidosis ,Spleen ,Diabetes Mellitus, Experimental - Published
- 1979
30. Enhancement of Amyloid Degradation by Ascorbic Acid: In Vivo Evidence in a Murine Model
- Author
-
B. Chen, I. Kedar, and M. Ravid
- Subjects
Sodium ascorbate ,Vitamin ,medicine.medical_specialty ,Vitamin C ,Amyloid ,Amyloidosis ,medicine.disease ,Ascorbic acid ,In vitro ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Biochemistry ,In vivo ,Internal medicine ,medicine - Abstract
In vitro experiments have shown that the amyloid degrading activity of amyloidotic sera could be restored by ascorbic acid, citric acid and by EDTA. It was therefore decided to test the influence of Vitamin C on experimental murine amyloidosis. Amyloidosis was induced during 14 days in three groups of 60 animals each. The first group received Vitamin C in the drinking water, as 3.5% solution, throughout the entire experimental period. Vitamin C was given to the second group after the induction of amyloidosis, while the control group received water alone. On the tenth, 17th, and 20th post induction days, 15 mice of each group were sacrificed. Their spleens were examined for the presence of amyloid. On the 17th day no amyloid was found in nine mice (out of 15) of the first group and in eight of the second. Small deposits were observed in five and three animals respectively. However, in the control groups giant deposits of amyloid were found in ten out of 15 animals. Amyloid degrading activity (ADA) of murine serum was examined in untreated, amyloidotic and Vitamin C treated animals. In healthy animals the ADA is unaffected by Vitamin C. In amyloidotic mice which have very low ADA initially, the addition of Vitamin C significantly increases the ADA. These results may possibly indicate that the in vitro effect of Vitamin C on amyloidotic sera is also expressed in an in vivo experimental model.
- Published
- 1986
- Full Text
- View/download PDF
31. In vitro synthesis of 'amyloid'fibrils from insulin, calcitonin and parathormone
- Author
-
I, Kedar, M, Ravid, and E, Sohar
- Subjects
Calcitonin ,Amyloid ,Mice ,Staining and Labeling ,Parathyroid Hormone ,Animals ,Insulin ,In Vitro Techniques ,Kidney ,Lysosomes - Abstract
Insulin, calcitonin and parathyroid hormone subjected to one of two procedures-acidification and heating or incubation with mouse kidney lysosomal extracts-assumed a nonbranching fibrillar structure, 7 to 10 nm in diameter. The preparations showed green birefringence after Congo red staining. The in vitro synthesis from different hormonal polypeptides of fibrils, fulfilling the criteria for the identification of amyloid, indicates that these criteria are related to conformational rather than to compositional properties, and suggests that these hormones may provide the subunit of the amyloid formed in the corresponding endocrine organs.
- Published
- 1976
32. Alleviation of experimental ischemic acute renal failure by dimethyl sulfoxide
- Author
-
I. Kedar, M. Ravid, J. Cohen, and Erwin T. Jacob
- Subjects
business.industry ,Dimethyl sulfoxide ,Acute Kidney Injury ,urologic and male genital diseases ,Kidney ,Rats ,Renal Circulation ,chemistry.chemical_compound ,chemistry ,Anesthesia ,Renal vessels ,Medicine ,Animals ,Urea ,Dimethyl Sulfoxide ,business - Abstract
Acute, ischemic renal failure was induced in rats by clamping of the renal vessels for 1 h. Following the termination of the ischemic period 5 g/kg of dimethyl sulfoxide (DMSO) were administered intravenously as a 20% solution in saline. Control animals received normal saline. There were not deaths among the DMSO-treated animals. Urine flow began within 15 min of DMSO infusion. 24 h after the experiment the mean blood urea was 73 +/- (SEM) 14 mg/100 ml (n = 29). All the control rats died during the week following the experiment. The mean blood urea at 24 h was 276 +/- 18 mg/100 ml (n = 20). In 10 additional animals perfusion of the kidney with DMSO prior to the closure of renal vessels protected the organ from ischemic damage. These experiments have a bearing on the therapeutic approach to ischemic renal failure in man, and on preservation methods of donor kidneys for transplantation.
- Published
- 1981
33. Degradation of amyloid by a serum component and inhibition of degradation
- Author
-
I, Kedar, E, Sohar, and M, Ravid
- Subjects
Adult ,Arthritis, Rheumatoid ,Liver Cirrhosis ,Amyloid ,Immunodiffusion ,Serum Amyloid A Protein ,Humans ,Amyloidosis ,Familial Mediterranean Fever - Abstract
ADA of human serum was demonstrated and investigated with an agar gel diffusion technique using amyloid-impregnated agar plates. Sera of 20 healthy adults, 40 patients with AA-amyloidosis, and 86 nonamyloidotic patients were tested. The presence of an ADF, showing enzymatic properties and strongly bound to albumin, was demonstrated in normals and amyloidotic and nonamyloidotic patients. ADA in the serum of amyloidotic and cirrhotic patients was markedly decreased due to the presence of an inhibitor of ADF. ADA of amyloidotic sera was restored to normal by EDTA, citric acid, and ascorbic acid. The ADA of 16 FMF patients and four of 34 patients with rheumatoid arthritis without amyloidosis was intermediate between normal and amyloidotic values, indicating the presence of lADF at low concentrations in these patients. These findings suggest that amyloid is a normal protein metabolite, possibly with a high metabolic turnover. Accumulation of amyloid may be caused by decrease of the ADA of the serum by its inhibitor, rather than by accelerated production.
- Published
- 1982
34. Dimethyl sulfoxide in acute ischemia of the kidney
- Author
-
N. Bar‐Natan, Erwin T. Jacob, M. Ravid, and I. Kedar
- Subjects
Male ,medicine.medical_treatment ,Ischemia ,Renal function ,Kidney ,General Biochemistry, Genetics and Molecular Biology ,Blood Urea Nitrogen ,Dogs ,History and Philosophy of Science ,medicine.artery ,medicine ,Animals ,Dimethyl Sulfoxide ,Renal artery ,Saline ,Renal ischemia ,business.industry ,General Neuroscience ,Acute Kidney Injury ,medicine.disease ,Nephrectomy ,Uremia ,Rats ,medicine.anatomical_structure ,Anesthesia ,Creatinine ,business - Abstract
Renal ischemia was produced in rats by clamping of the renal artery for 1 h. Upon termination of the ischemic period a 20% solution of DMSO (5 g/kg b.w.) was given intravenously to 33 rats. Eighteen control animals received normal saline. All DMSO-treated animals survived while all control animals died within the subsequent seven days. At 24 h following the experiment, the mean blood urea of the control rats was 254 mg/100 m1 and the mean plasma creatinine 7.2 mg/100 m1. By contrast, the DMSO-treated rats had a mean blood urea of 69 mg/100 m1 and plasma creatinine of 1.6 mg/100 m1. In 17 animals the kidney was perfused with DMSO prior to the closure of the renal artery. All these rats survived the procedure and showed near normal kidney function at 24 h. The renal artery was clamped for 60 min in ten dogs. Five dogs received DMSO (3 g/kg b.w.) and the other five received an equivalent dose of normal saline. Three weeks later a contralateral nephrectomy was performed. Renal function was normal in the DMSO-treated dogs. One control dog died of uremia, in the remaining four a transient renal failure was observed. These experiments in two different animals highlight the protective effect of DMSO on the ischemic kidney when the drug is administered after the ischemic period.
- Published
- 1983
35. Stimulation of murine amyloidosis by a dializable product from pretreated donors
- Author
-
I, Kedar, I, Bleiberg, and E, Sohar
- Subjects
Amyloid ,Mice ,Animals ,Caseins ,Transplantation, Homologous ,Amyloidosis ,Dialysis ,Spleen ,Tissue Donors ,Research Article - Abstract
Amyloid was obtained in recipient mice by implantation into their peritoneal cavity of a dialysis bag containing spleen cells obtained from donor mice which were treated with casein for 6 days and while no amyloid was found in their implanted spleens. The transplantations were performed with 2 cell systems, one containing whole spleen suspension and the other washed cells. Amyloid was obtained in the recipient mice within 6 days after the implantation and in a more massive quantity than in mice treated by casein for a similar period.
- Published
- 1975
36. Colchicine inhibition of casein-induced amyloidosis in mice
- Author
-
I, Kedar, M, Ravid, E, Sohar, and J, Gafni
- Subjects
Amyloid ,Time Factors ,Dose-Response Relationship, Drug ,Injections, Subcutaneous ,Caseins ,Amyloidosis ,Organ Size ,Disease Models, Animal ,Mice ,Animals ,Microscopy, Polarization ,Colchicine ,Injections, Intraperitoneal ,Spleen - Published
- 1974
37. Regression of amyloidosis secondary to granulomatous ileitis following surgical resection and colchicine administration
- Author
-
M, Ravid, J, Shapira, I, Kedar, and D, Feigl
- Subjects
Adult ,Nephrotic Syndrome ,Crohn Disease ,Ileum ,Humans ,Female ,Amyloidosis ,Colchicine ,Cecum - Abstract
A patient with nephrotic syndrome was found to have amyloidosis secondary to an otherwise asymptomatic Crohn's disease. Resection of a major portion of the affected bowel and long-term colchicine therapy were followed by a complete clinical remission of the nephrotic syndrome, most probably due to a significant resolution of amyloidosis. The combination of resection of affected bowel segments, together with long-term colchicine therapy may offer a better prognosis than either method alone.
- Published
- 1979
38. Dimethyl sulfoxide in experimental atherosclerosis of the rabbit
- Author
-
I, Kedar and E, Sohar
- Subjects
Male ,Disease Models, Animal ,Arteriosclerosis ,Animals ,Dimethyl Sulfoxide ,Rabbits ,Lipids ,Aorta - Published
- 1981
39. Demonstration of amyloid-degrading activity in normal human serum
- Author
-
Gafni J, E Sohar, and I Kedar
- Subjects
Amyloid ,Chemistry ,medicine.medical_treatment ,Amyloidosis ,Centrifugation ,In Vitro Techniques ,medicine.disease ,Molecular biology ,General Biochemistry, Genetics and Molecular Biology ,Biuret test ,Familial Mediterranean Fever ,Pathogenesis ,Blood ,medicine ,Humans ,Incubation ,Saline ,Total protein - Abstract
In systemic amyloidosis, the rare instances of recovery following the successful treatment of a predisposing disease present a challenge in the management of an otherwise fatal disorder 1,2. Notwithstanding, experimental endeavor has been directed largely toward unravelling the nature of amyloid and its pathogenesis rather than the biological mechanism by which this fibrillar protein may be removed from the tissues 3. The following experiments indicate that normal human serum contains a heat-stable component capable of degrading amyloid in vitro.Procedure. In principle, one portion of a standard suspension of water-soluble amyloid 4 was incubated with two portions of human serum in a test tube for 2 hr at 37°. Following incubation the precipitate obtained by centrifugation for 30 min in a cooled PC-2 Sorvall Centrifuge at 15,000 rpm was collected, twice washed in cold saline, and recentrifuged as above, resuspended in normal saline, and its total protein content determined by the Biuret method at 555 nm. ...
- Published
- 1974
40. Inhibition of amyloid synthesis in experimental animals by a protein free diet. A preliminary report
- Author
-
I, Kedar, M, Ravid, and E, Sohar
- Subjects
Amyloid ,Mice ,animal structures ,Glucose ,Liver ,Body Weight ,Animals ,Caseins ,Amyloidosis ,Dietary Proteins ,Articles ,Kidney ,Spleen - Abstract
Amyloidosis was induced by casein injections in mice allocated to glucose, purina and casein dietary regimens. Amyloid was not found in the glucose fed mice. By contrast, amyloid was present in the spleen of purina fed animals and in the spleen, liver and kidney of those fed casein. It seems therefore that adequate protein intake is essential for the consummation of an amyloidogenic stimulus.
- Published
- 1973
41. Treatment of experimental murine amyloidosis with dimethyl sulfoxide
- Author
-
KEIZMAN, I. KEDAR, primary, GREENWALD, M., additional, and RAVID, M., additional
- Published
- 1977
- Full Text
- View/download PDF
42. Prolonged Colchicine Treatment in Four Patients with Amyloidosis
- Author
-
I. Kedar, M. Robson, and Mordchai Ravid
- Subjects
Adult ,Male ,medicine.medical_specialty ,Nephrotic Syndrome ,Adolescent ,business.industry ,Amyloidosis ,Clinical course ,General Medicine ,Middle Aged ,medicine.disease ,Dermatology ,Systemic amyloidosis ,Familial Mediterranean Fever ,Colchicine treatment ,chemistry.chemical_compound ,chemistry ,Internal Medicine ,Humans ,Medicine ,Colchicine ,Female ,business - Abstract
The natural clinical course of four patients with systemic amyloidosis was favourably altered by continuous colchicine therapy. One patient had primary amyloidosis, and the other three suffered from amyloidosis of familial Mediterranean fever. All had a nephrotic syndrome, and one showed features of intestinal malabsorption. The institution of colchicine therapy was followed by a gradual remission of the nephrotic syndrome, a rise of serum albumin to normal values, a slight improvement of renal function, and regression of the intestinal malabsorption. This pattern has remained steady during an observation period of 30 months.
- Published
- 1977
- Full Text
- View/download PDF
43. The genetic landscape of Lynch syndrome in the Israeli population.
- Author
-
Shtaya AA, Nathan SN, Kedar I, Friedman E, Half E, Lidzbarsky G, Levi GR, Laish I, Katz L, Bazak L, Peretz LP, Salmon LB, Douiev L, Kalis ML, Schechter M, Barzily-Rokni M, Samra NN, Abu-Freha N, Hagari-Bechar O, Segol O, Mattar S, Barhom SF, Mordechai S, Rafid SS, Shalev SA, Peretz-Yablonski T, Levi Z, Bruchim R, Vinkler C, Bernstein-Molho R, Lieberman S, and Goldberg Y
- Subjects
- Humans, Israel epidemiology, Female, Male, Middle Aged, Adult, Genetic Predisposition to Disease, Jews genetics, Aged, Founder Effect, DNA Mismatch Repair genetics, Colorectal Neoplasms, Hereditary Nonpolyposis genetics, MutS Homolog 2 Protein genetics
- Abstract
Deciphering the spectrum and founder disease-causing variants (DCVs) in specific populations can shape and facilitate the diagnostic process of Lynch Syndrome (LS). The aim of this report was to comprehensively update on the genetic landscape of LS in the ethnically diverse Israeli-Jewish population. The cohort included 1080 carriers from 588 families; some from underrepresented, understudied Israeli ethnic groups recruited from 8 genetic institutes and high-risk clinics throughout the country. Variant classification was performed according to the American College of Medical Genetics criteria. A total of 157 DCVs were identified, 12 are reported here for the first time, and 9 reclassified. MSH2 DCVs were identified in 286 families (49%). Most DCVs (125/157, 80%) were noted in one or two families only. Sixteen DCVs, each detected in ≥ 5 families, and accounted for LS in 378/588 (64%) families. Constitutional mismatch repair deficiency (CMMRD) was diagnosed in 7 families. Twenty-five carriers (2.3%) had an additional DCV or risk alleles in another cancer susceptibility gene. In conclusion, MMR gene variant distribution in Israel is diverse. MSH2 is most commonly mutated due to founder DCVs. Though the 16 prevalent LS-associated DCVs were frequently detected in our cohort, none of them is frequently reported in the general population. These data should facilitate variant interpretation, spouse and cascade testing., Competing Interests: Declarations Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
- Author
-
Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner FL, Voet H, Bareket-Samish A, Kedar I, Goldberg Y, Peretz-Yablonski T, and Kadouri L
- Subjects
- Humans, Female, Middle Aged, Aged, Retrospective Studies, Biomarkers, Tumor genetics, Germ-Line Mutation, Mutation, Heterozygote, Adult, Genetic Predisposition to Disease, Breast Neoplasms genetics, Breast Neoplasms pathology, BRCA2 Protein genetics, BRCA1 Protein genetics
- Abstract
Purpose: We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested BC population., Methods: This retrospective study included consecutive 21-gene-tested female ER + HER2-negative BC patients with germline PVs in BRCA1/2. RS/gene expression data were compared to a previously described commercial use database (CDB, N = 799,986). Chi-square and 1-sample t test were used to compare RS distribution and single-gene/gene group scores between the study group and the CDB., Results: Study group patients (N = 81) were younger and their RS results were higher compared to the CDB (age: median [IQR], 56 [47-61.5] vs 60 [51-67] years; p < 0.001; proportion of patients with RS ≥ 26: 49.4% vs 16.4%, p < 0.001). Expression of 12/16 cancer genes in the assay and the ER, proliferation, and invasion gene group scores differed significantly between the study group and the CDB, all in a direction contributing to higher RS. The differences between the study group and the CDB were mostly retained, upon stratifying the patients by menopausal status., Conclusion: BC patients with PVs in BRCA1/2 have higher RS results that stem from distinct gene expression profiles in the majority of genes in the 21-gene assay., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies.
- Author
-
Abu Shtaya A, Kedar I, Bazak L, Basel-Salmon L, Barhom SF, Naftali M, Eskin-Schwartz M, Birk OS, Polager-Modan S, Keidar N, Reznick Levi G, Levi Z, Yablonski-Peretz T, Mahamid A, Segol O, Matar R, Bareli Y, Azoulay N, and Goldberg Y
- Subjects
- Male, Humans, Female, Adult, Middle Aged, Aged, Telomere-Binding Proteins genetics, Shelterin Complex, Melanoma genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Skin Neoplasms genetics, Thyroid Neoplasms
- Abstract
POT1 (Protection of Telomeres 1) is a key component of the six-membered shelterin complex that plays a critical role in telomere protection and length regulation. Germline variants in the POT1 gene have been implicated in predisposition to cancer, primarily to melanoma and chronic lymphocytic leukemia (CLL). We report the identification of POT1 p.(I78T), previously ranked with conflicting interpretations of pathogenicity, as a founder pathogenic variant among Ashkenazi Jews (AJs) and describe its unique clinical landscape. A directed database search was conducted for individuals referred for genetic counselling from 2018 to 2023. Demographic, clinical, genetic, and pathological data were collected and analyzed. Eleven carriers, 25 to 67 years old, from ten apparently unrelated families were identified. Carriers had a total of 30 primary malignancies (range 1-6); nine carriers (82%) had recurrent melanoma between the ages of 25 and 63 years, three carriers (27%) had desmoid tumors, three (27%) had papillary thyroid cancer (PTC), and five women (63% of female carriers) had breast cancer between the ages of 44 and 67 years. Additional tumors included CLL; sarcomas; endocrine tumors; prostate, urinary, and colorectal cancers; and colonic polyps. A review of a local exome database yielded an allelic frequency of the variant of 0.06% among all ethnicities and of 0.25% in AJs. A shared haplotype was found in all carriers tested. POT1 p.(I78T) is a founder disease-causing variant associated with early-onset melanoma and additional various solid malignancies with a high tumor burden. We advocate testing for this variant in high-risk patients of AJ descent. The inclusion of POT1 in germline panels for various types of cancer is warranted.
- Published
- 2024
- Full Text
- View/download PDF
46. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
- Author
-
Ben-Zion Berliner M, Yust-Katz S, Lavie I, Goldberg Y, Kedar I, and Yerushalmi R
- Subjects
- Female, Humans, Central Nervous System, Germ Cells pathology, Germ-Line Mutation, Matched-Pair Analysis, Prognosis, Retrospective Studies, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms pathology, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms secondary
- Abstract
Background: Breast cancer is a common cause for central nervous system (CNS) metastasis, resulting in a significant reduction in overall survival. Germline pathogenic variants (PVs) in BRCA1/2 are the most common genetic risk factor for breast cancer, associated with poor prognostic factors. This study sought to explore the patterns and outcome of CNS metastases in breast cancer patients with germline PVs in BRCA1/2 genes., Methods: A retrospective cohort of 75 breast cancer patients with known BRCA1/2 mutation status, who were diagnosed with CNS metastases in 2006-2021. Histopathology, characteristics of CNS disease, treatments, and survival were compared between BRCA1/2 carriers (n = 25) and non-carriers (n = 50), using propensity score matching (1:2 ratio) to control for the possible influence of tumor receptor status (ER, PR, HER2) and patient age. Pearson chi-square or Fisher exact test and Kaplan-Meier survival curves with log-rank test were used for statistical analyses., Results: Patients with PVs in BRCA1/2 had more high-grade tumors (88% vs. 68%, P = 0.060), were younger at CNS disease diagnosis (median 46.69 vs. 55.02 years, P = 0.003) and had better ECOG performance status (ECOG PS 0 in 20% vs. 2%, P = 0.033), but without significant differences in systemic or CNS-directed treatment approaches. BRCA1/2 mutation was associated with a higher rate of temporal lobe involvement (52% vs. 26%, P = 0.026) and leptomeningeal spread (40% vs. 20%, P = 0.020). Survival after diagnosis of CNS disease was shorter (median 8.03 vs. 28.36 months, P < 0.0001), with no significant differences in time to development of CNS metastases or overall-survival., Conclusion: Patients with CNS metastatic breast cancer and PVs in BRCA1/2 showed a higher rate of leptomeningeal and temporal lobe involvement, and a shorter survival with CNS disease. To the best of our knowledge, this is the first study suggesting an exclusive impact of germline BRCA1/2 mutations in CNS metastatic breast cancer., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
47. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
- Author
-
Laish I, Schechter M, Dancour A, Lieberman S, Levi Z, Goldberg Y, Kedar I, Hasnis E, Half E, Levi GR, Katz L, Vainer ED, Genzel D, Aharoni M, Chen-Shtoyerman R, Abu-Freha N, Raitses-Gurevich M, Golan T, Bernstein-Molho R, Ben Yehoyada M, Gluck N, and Rosner G
- Subjects
- Humans, BRCA1 Protein genetics, Cohort Studies, BRCA2 Protein genetics, Germ Cells, Genetic Predisposition to Disease, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms genetics, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal epidemiology, Carcinoma, Pancreatic Ductal genetics, Adenocarcinoma diagnosis, Adenocarcinoma epidemiology, Adenocarcinoma genetics
- Abstract
Background: Surveillance of high-risk individuals for pancreatic ductal adenocarcinoma (PDAC) is recommended. This study aimed to determine the prevalence and outcomes of PDAC and its precursor lesions in BRCA1/2 pathogenic variants (PVs) carriers undergoing pancreatic surveillance., Methods: A retrospective multicenter cohort study of pancreatic surveillance outcomes in Israeli BRCA1/2 carriers preferably with a family history of PDAC., Results: A total of 180 asymptomatic carriers participated in the screening programs, including 57 (31.7%) with BRCA1 PVs, 121 (67.2%) with BRCA2 PVs, and 12 (6.6%) with PVs in BRCA1/2 and other genes, for a median follow-up period of 4 years. Ninety-one individuals (50.5%) fulfilled the International Cancer of the Pancreas Screening (CAPS) criteria for surveillance whereas 116 (64.4%) fulfilled the American College of Gastroenterology (ACG) criteria. There were four cases of adenocarcinoma and four cases of grade 1-neuroendocrine tumor (G1-NET). All were BRCA2 carriers, and two had no family history of PDAC. Three cancer patients were at resectable stages (IA, IIA, IIB) whereas one had a stage IIIB tumor. Of the G1-NET cases, one had surgery and the others were only followed. Success rate for detection of confined pancreatic carcinoma was thus 1.6% (three of 180) in the whole cohort, 1.6% (two of 116) among individuals who fulfilled ACG criteria and 2.2% (two of 91) in those fulfilling CAPS criteria for surveillance., Conclusions: Despite the low detection rate of PDAC and its' high-risk neoplastic precursor lesions among BRCA1/2 carriers undergoing pancreatic surveillance, 75% of cancer cases were detected at a resectable stage., (© 2023 American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
48. The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort.
- Author
-
Abu Shtaya A, Kedar I, Mattar S, Mahamid A, Basel-Salmon L, Farage Barhom S, Naftaly Nathan S, Magal N, Azulay N, Levy Zalcberg M, Chen-Shtoyerman R, Segol O, Seri M, Reznick Levi G, Shkedi-Rafid S, Vinkler C, Netzer I, Hagari Bechar O, Chamma L, Liberman S, and Goldberg Y
- Abstract
Founder pathogenic variants (PVs) are prevalent in Israel. This study investigated the current practice of offering cancer patients two-step genetic testing, starting with targeted testing for recurring founder PVs, followed, if negative, by next-generation sequencing. A total of 2128 subjects with cancer or a positive family history underwent oncogenetic testing with a panel of 51 recurring PVs at a tertiary medical center in March 2020-January 2023. Those with a known familial PV (n = 370) were excluded from the analysis. Among the remainder, 128/1758 (7%) were heterozygous for at least one variant, and 44 (34%) carried a PV of medium-high penetrance (MHPV). Cancer was diagnosed in 1519/1758 patients (86%). The diagnostic yield of founder MHPV testing was 2% in cancer patients and 4% in healthy individuals with a positive family history. It was higher in Ashkenazi Jews than non-Ashkenazi Jews and Arabs, but not over 10% for any type of cancer, and it was significantly higher in younger (<40 years) than older (>50 years) individuals (7% vs. 1%). Eighty-four of the heterozygotes (66%), mostly Ashkenazi Jews, harbored a low-penetrance variant (LPV) not associated with the diagnosed cancer, usually APC c.3902T>A. These findings question the advantage of two-step testing. LPVs should not be included in targeted testing because this can lead to an overestimation of the yield, and their detection does not preclude further comprehensive testing.
- Published
- 2023
- Full Text
- View/download PDF
49. High prevalence of MUTYH associated polyposis among minority populations in Israel, due to rare founder pathogenic variants.
- Author
-
Reznick Levi G, Goldberg Y, Segev H, Maza I, Gorelik Y, Laish I, Levi Z, Kedar I, Naftali Nathan S, Sharon Swartzman N, Abu Freha N, Paritsky M, Rennert G, Baris Feldman H, Paperna T, Weiss K, and Half EE
- Subjects
- Humans, Child, Israel epidemiology, Prevalence, Health Disparate Minority and Vulnerable Populations, Mutation, Genetic Predisposition to Disease, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology
- Abstract
Background: Autosomal recessive conditions are common in consanguineous populations. Since consanguinity is common in the Israeli Arab population, we evaluated the rate of MUTYH polyposis (MAP) among polyposis patients in this population and studied Pathogenic Variants (PVs) spectrum., Methods: We reviewed health records of all Arab and Druze polyposis patients referred for counseling during 2013-2020 who fulfilled the Israeli Genetic Society criteria for MUTYH/APC testing, in a tertiary center in Northern Israel and four additional gastro-genetic clinics in Israel., Results: The Northern cohort included 37 patients from 30 unrelated families; 8(26.6%) carried bi-allelic MUTYH PVs. The major variant p.Glu452del was detected in 6/8 Druze and Muslim families who shared the same haplotype. Other PVs detected in both cohorts included p.Tyr56Ter, p.His57Arg, c.849+3A>C, p.Ala357fs, and p.Tyr151Cys. Among bi-allelic carriers, 88% reported consanguinity, and 100% had positive family history for polyposis or colorectal cancer (CRC). Generally, the age of CRC was 10 years younger than reported in the general MAP population., Conclusions: MAP accounted for 27% of polyposis cases in the Arab population of Northern Israel. PVs spectrum is unique, with high frequency of the founder variant p.Glu452del. Our results may inform the genetic testing strategy in the Israeli Arab population., Competing Interests: Conflict of interest No conflict of interest declared by the authors., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
50. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].
- Author
-
Michaelson-Cohen R, Laitman Y, Kedar I, Baris-Feldman H, Reish O, Lieberman S, Bernstein-Molho R, Goldberg Y, Reznick Levi G, Gershoni R, Beller U, Levy-Lahad E, Catan R, and Friedman E
- Subjects
- Humans, Female, Israel epidemiology, Retrospective Studies, Genes, BRCA1, Neoplasm Recurrence, Local, BRCA2 Protein genetics, BRCA1 Protein genetics, Genetic Association Studies, Jews genetics, Mutation, Genetic Predisposition to Disease, Ovarian Neoplasms epidemiology, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Breast Neoplasms epidemiology, Breast Neoplasms genetics
- Abstract
Introduction: Hereditary breast and ovarian cancer (HBOC) is predominantly accounted for by pathogenic variants (PVs) in BRCA1/BRCA2 genes. Population screening for recurring PVs in Ashkenazi Jews (AJ) was incorporated into the Israeli health basket in 2020, increasing the identification of BRCA carriers. Information on cancer risks for each PV in Israel is limited., Aims: To assess genotype phenotype correlations of recurring BRCA PVs in Israeli carriers., Methods: A retrospective cohort of 3,478 BRCA carriers followed-up in 12 medical centers, comprising the HBOC Consortium, formed the basis of the study. Data were collected using the electronic database, and analyzed by Chi square, t-tests and Kaplan-Meier survival analysis., Results: Overall, 2145 BRCA1, 1131 BRCA2, and 22 double heterozygote PV carriers were analyzed. BRCA1 carriers had more cases of cancer (53.1% vs. 44.8%, p<0.001), ovarian cancer (OC) (17.1% vs. 10.6%, p<0.001), younger age at breast cancer (BC) (45.4 ±11.6SD years vs. 49.1 ±11.1SD years, p<0.001) and OC diagnosis (52.8 ±10.1SD yrs. vs. 61±10.6SD yrs. p<0.001), and more family history of BC (64.5% vs. 59.0%, p<0.001) and OC (36.7% vs. 27.3%, p<0.001) compared with BRCA2 carriers. Carriers of BRCA15382insC had more BC and less OC than BRCA1185delAG: 46.4% vs. 38.6% and 12.9% vs. 17.6% (p<0.04), respectively., Conclusions: In our population, similar to others, BRCA1 carriers have higher cancer rates and earlier age at diagnosis compared with BRCA2 carriers. The two recurring BRCA1 PVs have different risks: 5382insC carriers had more BC; 185delAG carriers had more OC. Risk-reducing measures should be based on variant-specific cancer risk.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.